Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 6/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.70 |
| ▸ | POLB | P06746 | 3/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.55 |
| ▸ | RAB9A | P51151 | 3/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | CHEK1 | O14757 | 3/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4298475 | 0.91 | MEN1 (0.71) | MEN1KMT2APOLBKDM4ERAB9A | |
| SCHEMBL5372771 | 0.87 | MEN1 (0.71) | MEN1KMT2APOLBKDM4ERAB9A | |
| SCHEMBL4302504 | 0.86 | CHEK1 (0.52) | MEN1KMT2APOLBRAB9ACHEK1 | |
| SCHEMBL13665414 | 0.86 | KMT2A (0.72) | MEN1KMT2APOLBKDM4ERAB9A | |
| SCHEMBL5378857 | 0.85 | KMT2A (0.71) | MEN1KMT2APOLBKDM4ERAB9A | |
| SCHEMBL14517933 | 0.84 | MEN1 (0.67) | MEN1KMT2APOLBKDM4ERAB9A | |
| SCHEMBL5372352 | 0.83 | KMT2A (0.72) | MEN1KMT2APOLBKDM4ERAB9A | |
| SCHEMBL5372209 | 0.83 | KMT2A (1.00) | MEN1KMT2APOLBKDM4ERAB9A | |
| SCHEMBL4303358 | 0.83 | CHEK1 (0.72) | CHEK1 | |
| SCHEMBL5382593 | 0.83 | MEN1 (0.71) | MEN1KMT2APOLBKDM4ERAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090270416-A1 | N-OXIDES OF DIARYLUREA DERIVATIVES AND THEIR USE AS Chk1 INHIBITORS FOR THE TREATMENT OF CANCER | SENTINEL ONCOLOGY LIMITED (GB) | 2009-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270416-A1 | N-OXIDES OF DIARYLUREA DERIVATIVES AND THEIR USE AS Chk1 INHIBITORS FOR THE TREATMENT OF CANCER | CHEK1, CHEK2, CDK1 | MEN1 2156/4885KMT2A 888/4885POLB 836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.